Talphera (TLPH) Competitors $0.71 +0.04 (+6.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TLPH vs. TARA, ACAB, IMMX, GANX, CALC, SCYX, SNYR, ACHL, AFMD, and BLRXShould you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Protara Therapeutics (TARA), Atlantic Coastal Acquisition Corp. II (ACAB), Immix Biopharma (IMMX), Gain Therapeutics (GANX), CalciMedica (CALC), SCYNEXIS (SCYX), Synergy CHC Corp. (Uplisting) (SNYR), Achilles Therapeutics (ACHL), Affimed (AFMD), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry. Talphera vs. Protara Therapeutics Atlantic Coastal Acquisition Corp. II Immix Biopharma Gain Therapeutics CalciMedica SCYNEXIS Synergy CHC Corp. (Uplisting) Achilles Therapeutics Affimed BioLineRx Protara Therapeutics (NASDAQ:TARA) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, community ranking, valuation, earnings and profitability. Does the MarketBeat Community favor TARA or TLPH? Protara Therapeutics received 28 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 65.38% of users gave Protara Therapeutics an outperform vote. CompanyUnderperformOutperformProtara TherapeuticsOutperform Votes3465.38% Underperform Votes1834.62% TalpheraOutperform Votes6100.00% Underperform VotesNo Votes Is TARA or TLPH more profitable? Protara Therapeutics' return on equity of -55.96% beat Talphera's return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -55.96% -49.06% Talphera N/A -118.46%-65.82% Which has more risk and volatility, TARA or TLPH? Protara Therapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Talphera has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Does the media refer more to TARA or TLPH? In the previous week, Protara Therapeutics had 5 more articles in the media than Talphera. MarketBeat recorded 11 mentions for Protara Therapeutics and 6 mentions for Talphera. Talphera's average media sentiment score of 0.72 beat Protara Therapeutics' score of 0.12 indicating that Talphera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Talphera 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in TARA or TLPH? 38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 12.5% of Protara Therapeutics shares are held by company insiders. Comparatively, 3.2% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation & earnings, TARA or TLPH? Talphera has higher revenue and earnings than Protara Therapeutics. Talphera is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$40.42M-$2.82-0.82Talphera$650K18.51-$18.40M-$0.69-1.02 Do analysts rate TARA or TLPH? Protara Therapeutics currently has a consensus target price of $24.00, indicating a potential upside of 938.96%. Talphera has a consensus target price of $4.50, indicating a potential upside of 537.03%. Given Protara Therapeutics' higher probable upside, equities analysts plainly believe Protara Therapeutics is more favorable than Talphera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Talphera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryProtara Therapeutics beats Talphera on 10 of the 17 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Talphera News Delivered to You Automatically Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLPH vs. The Competition Export to ExcelMetricTalpheraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.03M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-1.025.5697.3414.18Price / Sales18.51348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book0.857.885.805.12Net Income-$18.40M$153.61M$119.07M$225.99M7 Day Performance2.14%-2.00%-1.83%-1.32%1 Month Performance-32.34%-7.47%-3.64%0.60%1 Year PerformanceN/A31.80%31.62%26.23% Talphera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLPHTalphera2.6915 of 5 stars$0.71+6.0%$4.50+537.0%N/A$12.03M$650,000.00-1.0219Gap UpTARAProtara Therapeutics2.1378 of 5 stars$2.31-0.4%$24.00+939.0%+102.6%$47.86MN/A0.0030Analyst RevisionACABAtlantic Coastal Acquisition Corp. IIN/A$5.77-47.1%N/A-45.6%$47.14MN/A0.004High Trading VolumeIMMXImmix Biopharma2.28 of 5 stars$1.82+7.1%$7.00+284.6%-58.7%$46.76MN/A0.009Negative NewsHigh Trading VolumeGANXGain Therapeutics2.4867 of 5 stars$1.66-3.5%$7.33+341.8%-39.0%$45.62M$50,000.000.0020News CoverageGap DownCALCCalciMedica3.0723 of 5 stars$3.45+3.0%$19.33+460.4%+10.6%$45.16MN/A0.0030SCYXSCYNEXIS2.1937 of 5 stars$1.18flatN/A-28.5%$44.78M$140.14M0.0060Positive NewsSNYRSynergy CHC Corp. (Uplisting)N/A$5.82-1.4%N/AN/A$44.57MN/A0.0040Gap UpACHLAchilles Therapeutics2.3832 of 5 stars$1.07+1.9%$4.00+273.8%+32.1%$43.98MN/A-0.65250AFMDAffimed3.5267 of 5 stars$2.72-9.3%$16.00+488.2%-42.7%$43.79M$8.95M0.0076Analyst ForecastBLRXBioLineRx1.9598 of 5 stars$0.55+1.9%$21.00+3,751.8%-67.9%$43.58M$17.05M-1.2140News Coverage Related Companies and Tools Related Companies Protara Therapeutics Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Immix Biopharma Alternatives Gain Therapeutics Alternatives CalciMedica Alternatives SCYNEXIS Alternatives Synergy CHC Corp. (Uplisting) Alternatives Achilles Therapeutics Alternatives Affimed Alternatives BioLineRx Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TLPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talphera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talphera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
